Outlook TherapeuticsOTLK -1.69%16 Days Inventory is 2,082.83 as of Mar. 2026, which is 132% above its 10-year median of 897.84. GuruFocus rates OTLK with a GF Score™ of 16/100. The stock has 5 warning signs investors should review. Among 637 Biotechnology companies, Outlook Therapeutics ranks worse than 88.85% on this metric.
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Outlook Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Outlook Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 26.78.
Outlook Therapeutics (NAS:OTLK) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Outlook Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Outlook Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Outlook Therapeutics Days Inventory Related Terms
Outlook Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Outlook Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTLK vs FULC, OBIO, ACIU: Days Inventory Comparison
For the Biotechnology subindustry, Outlook Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Outlook Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Outlook Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics (OTLK) has a Days Inventory of 2,082.83 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Outlook Therapeutics and its competitors. This is 132% above median its historical median of 897.84. Over the past decade, Outlook Therapeutics' Days Inventory has ranged from 851.05 to 897.84. According to the industry distribution chart, Outlook Therapeutics ranks #566 out of 637 companies in the Biotechnology industry, placing it in the top 88.9%.
Is Outlook Therapeutics' Days Inventory too high?
Outlook Therapeutics' current Days Inventory of 2,082.83 is 132% above median its 10-year median of 897.84. Over the past 10 years, this metric has ranged from a low of 851.05 to a high of 897.84. The Biotechnology industry median Days Inventory is 183.37. Outlook Therapeutics' value of 2,082.83 is 1035.9% above this industry median. Based on the distribution chart, Outlook Therapeutics ranks #566 out of 637 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Outlook Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Days Inventory compare to FULC and OBIO?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #566 out of 637 companies for Days Inventory. This places Outlook Therapeutics in the lower half of its industry. The industry median Days Inventory is 183.37. Outlook Therapeutics' value of 2,082.83 is 1035.9% above this benchmark. Historically, Outlook Therapeutics' own Days Inventory has ranged from 851.05 to 897.84 over the past decade. While the company's 10-year median is 897.84 vs. the industry median of 183.37, Outlook Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.37, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Outlook Therapeutics's current Days Inventory of 2,082.83 is 1035.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Outlook Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 183.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Outlook Therapeutics's current Days Inventory is 2,082.83, which is 132% above median its own 10-year median of 897.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Days Inventory of 2,082.83. The current Days Inventory is 2,082.83, which is 132% above median its 10-year median of 897.84 and 1035.9% above the Biotechnology industry median of 183.37. Outlook Therapeutics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Days Inventory is 2,082.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
16GF Score
Get the complete analysis for OTLK
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLK has been successfully added to your 
